Session 3 Panel Discussion

Video Overview

Kim Bure, Director of Regenerative Medicine at Sartorius Stedium Biotech, moderated the third panel of the conference – joined by speakers David Brindley, Eric Roos and Jeanne Loring. The panellists discussed topics including whether the level of thoroughness in pre-clinical work expected by regulators is truly appropriate, as well as the implications of rapidly-improving data collection workflows for clinical trials. Continuing, the panel answered audience questions on regulatory consultants, the logistics of delivering advanced therapies, and whether primary tissue grafts may be of greater therapeutic value than single purified cell types.